VYRIAD INC
Where Therapies Go Viral
- Headquarters
- Rochester, Minnesota
- Employees
- 11–50
- Founded
- 2017
- Business Model
- B2B
- Website
- vyriad.com
- Total Funding
- $124.5M
- Last Round
- $85.0M Series BDec 2025
- Rounds
- 3
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 3 funding rounds and 4 investors for this company. to use credits for reveals, or explore the API.
About
Vyriad is a clinical-stage biotechnology company founded by Mayo Clinic scientists developing engineered virus platforms for oncolytic virotherapy, in vivo gene therapy, and gene editing. The company's VSV and measles virus-based therapies are in Phase 1-2 clinical trials across multiple cancer types, with an ongoing strategic collaboration with Regeneron Pharmaceuticals.
Funding History
Dec 2025
2 more funding events
- Series B2022
- Series A2017
Funding: Series A through Series B. Amounts, valuations, and investors where available.
Investors
Tech & App Stack
5 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
- Marketing & SEO ×2
- Backend ×1
- Frontend ×1
- Productivity & Collaboration ×1
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Companies in related industries
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
Novel bicyclic peptides and drug conjugates for cancer
China's leading blood products manufacturer
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/vyriad-inc"><img src="https://indexed.vc/api/badge/company/vyriad-inc" alt="VYRIAD INC on Indexed.vc" width="260" height="76" /></a>


